Rosai-Dorfman-Destombes disease (RDD) is a rare, benign histiocytic disorder, most often involving lymph nodes but showing ...

PURPOSE: In the International Lymphoma Study Group classification of lymphoma, extranodal marginal zone B-cell lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) type is listed as a ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% ...

Outcomes in newly diagnosed diffuse large B cell lymphoma presenting with hepatic and/ or renal dysfunction. Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from his presentation on extranodal marginal zone ...

In early research, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma. In early research led by the University of ...

Please provide your email address to receive an email when new articles are posted on . In this video, Joshua Brody, MD, discusses results from the ongoing phase 2 MorningSun trial of subcutaneous ...

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...

Primary cutaneous B-cell lymphoma is a heterogeneous group of malignant lymphomas. Primary cutaneous B-cell lymphomas are the second most common group of extranodal lymphomas after mucosa-associated ...

Classifying non-Hodgkin lymphoma (NHL) can be confusing because there are so many types. The World Health Organization system is often used. It groups NHL by the appearance of the lymphoma cells, the ...

—Screening for multiple mucosal sites in patients with EMZL may be prudent. Affected patients are a distinct subset, possibly with shorter OS and PFS. Reviewed by Chaitra Ujjani, MD, Associate ...